Pfizer misses revenue estimates as COVID product sales decline
The company has said it expects 2023 to be a low point for COVID product sales following strong demand at the peak of the pandemic before a potential return to growth in 2024. "Clearly, there is a higher level of uncertainty regarding the demand projections for our COVID-19 products than for the rest of the business," CEO Albert Bourla said. However, the company maintained its forecast for annual COVID revenues at about $21.5 billion.
Source: yahoo.com